Regeneron Pharmaceuticals, Inc.

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 7, 2025), Regeneron Pharmaceuticals, Inc. reported 6 stock positions worth $1.1 billion. Its top holding was Alnylam Pharmaceuticals (ALNY) at 95.5% of the portfolio, followed by Intellia Therapeutics (NTLA, 3.9%) and 2SEVENTY Bio (TSVT, 0.3%).

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$1.1B (Q4 2024)
SEC Filing
0001104659-25-010583 ↗ filed Feb 7, 2025

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B Q2 2025 Q3 2025: $700.4M Q3 2025 Q4 2025: $33.8M Q4 2025 Q1 2026: $47.9M Q1 2026 Q2 2026: $177.2M Q2 2026

Holdings 6 stocks · $1.1B
ALNY Alnylam Pharmaceuticals Inc. 95.54% 4,444,445 $1.0B —
NTLA Intellia Therapeutics Inc. 3.94% 3,702,995 $43.2M —
TSVT 2SEVENTY Bio Inc. 0.34% 1,254,827 $3.7M —
ACET Adicet Bio Inc. 0.09% 968,183 $931K —
ADVM Adverum Biotechnologies Inc. 0.08% 180,909 $845K —
BLUEBIRD BIO INC 0.02% 21,000 $175K —

Portfolio Sells Q4 2024

No earlier filing to compare with.

Portfolio Buys Q4 2024

No earlier filing to compare with.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM